Home    Back

Tas5315 low dose    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
46Malignant rheumatoid arthritis1

46. Malignant rheumatoid arthritis    [ 4,183 clinical trials,   2,538 drugs,   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways]
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 4,183 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03605251
(ClinicalTrials.gov)		August 30, 20183/7/2018Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.An Early Phase-II, Randomized, Double-blind, Study of TAS5315 in Rheumatoid Arthritis Patients With an Inadequate Response to MethotrexateRheumatoid ArthritisDrug: TAS5315 low dose;Drug: TAS5315 high dose;Drug: PlacebosTaiho Pharmaceutical Co., Ltd.NULLCompleted20 Years64 YearsAll91Phase 2Japan